CA2443089C - Antifungal suspension of micronized posaconazole - Google Patents
Antifungal suspension of micronized posaconazole Download PDFInfo
- Publication number
- CA2443089C CA2443089C CA2443089A CA2443089A CA2443089C CA 2443089 C CA2443089 C CA 2443089C CA 2443089 A CA2443089 A CA 2443089A CA 2443089 A CA2443089 A CA 2443089A CA 2443089 C CA2443089 C CA 2443089C
- Authority
- CA
- Canada
- Prior art keywords
- liquid
- suspension
- posaconazole
- liquid suspension
- sorbitan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 title claims description 53
- 229960001589 posaconazole Drugs 0.000 title claims description 53
- 239000000725 suspension Substances 0.000 title claims description 35
- 230000000843 anti-fungal effect Effects 0.000 title description 7
- 229940121375 antifungal agent Drugs 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 239000006194 liquid suspension Substances 0.000 claims abstract description 47
- 239000007788 liquid Substances 0.000 claims abstract description 36
- 239000002562 thickening agent Substances 0.000 claims abstract description 26
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 55
- 239000002245 particle Substances 0.000 claims description 28
- -1 polyoxyethylene Chemical class 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000230 xanthan gum Substances 0.000 claims description 18
- 229920001285 xanthan gum Polymers 0.000 claims description 18
- 229940082509 xanthan gum Drugs 0.000 claims description 18
- 235000010493 xanthan gum Nutrition 0.000 claims description 18
- 229940100692 oral suspension Drugs 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 239000008213 purified water Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 206010017533 Fungal infection Diseases 0.000 claims description 11
- 208000031888 Mycoses Diseases 0.000 claims description 11
- 235000013861 fat-free Nutrition 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- 235000012054 meals Nutrition 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 3
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 3
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 3
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 125000005908 glyceryl ester group Chemical group 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
- 239000001593 sorbitan monooleate Substances 0.000 claims description 3
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 3
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 3
- 239000001570 sorbitan monopalmitate Substances 0.000 claims description 3
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 3
- 239000001587 sorbitan monostearate Substances 0.000 claims description 3
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims description 3
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 3
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 3
- 235000011078 sorbitan tristearate Nutrition 0.000 claims description 3
- 239000001589 sorbitan tristearate Substances 0.000 claims description 3
- 229960004129 sorbitan tristearate Drugs 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 29
- 238000009472 formulation Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 235000021152 breakfast Nutrition 0.000 description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 9
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 9
- 239000004299 sodium benzoate Substances 0.000 description 9
- 235000010234 sodium benzoate Nutrition 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 229940068968 polysorbate 80 Drugs 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229940083037 simethicone Drugs 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007958 cherry flavor Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229940096325 posaconazole oral suspension Drugs 0.000 description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920005682 EO-PO block copolymer Polymers 0.000 description 2
- 229920002884 Laureth 4 Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920001363 Polidocanol Polymers 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical class CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 229940053336 lauromacrogols Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
- A01N43/647—Triazoles; Hydrogenated triazoles
- A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula (I) at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.
Description
ANTIFUNGAL SUSPENSION OF MICRONIZED POSACONAZOLE
BACKGROUND OF THE INVENTION
This invention relates to stable, liquid suspensions containing an antifungally effective amount of the micronized compound represented by the chemical structural formula I:
H& /\ N N \ ! N N S
N
HO
F R O
N
F ~=N
at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier, and methods of using the suspensions to treat or prevent fungal infections U.S. Patent No. 5,661,151 discloses the compound of formula I and its potent antifungal activity against a broad range of fungi such as Aspergillis, Candida, Cryptococcus, Fusarium, and other opportunistic fungi.
U.S. Patent Nos. 5,834,472 and 5,846,971, disclose oral pharmaceutical capsule compositions of the compound of structural formula I coated onto inert beads together with a binder. However, the compound of structural formula I is highly lipophilic, and has an extremely low water solubility. Thus, aqueous compositions of the compound of structural formula I were found to have reduced anti-fungal activity and/or bioavailability, presumably due to the extremely low water solubility of the compound. Accordingly, a need exists for an oral pharmaceutical composition of the compound of structural formula I that has enhanced bioavailability and improved stability characteristics SUMMARY OF THE INVENTION
We have found pharmaceutical compositions, in the form of liquid suspension, suitable for oral administration comprising micronized particles of posaconazole, the compound having the chemical structural formula I
F F H ~\\\O NN NN (S) N H\`, OH
(R) N-N
N
at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier that provides significant advantages over the prior art.
Advantages of the liquid suspensions of the present invention include improved homogeneity of the suspension and ease of dispersibility of the suspension. The solids that settle in the liquid suspension of the present invention do not form a solid cake that is difficult to re-disperse. There is virtually no sedimentation of the solids in the unreconstituted liquid suspension of this invention for a period of at least three days. This surprising feature ensures that a patient having a fungal infection taking the liquid suspensions of the present invention will receive an antifungally effective amount of posaconazole. The liquid suspensions of the present invention have a longer shelf life. Additionally, the liquid suspension, upon reconstitution, provide substantially the same antifungally effective amount posaconazole as the initially prepared suspension. These features of the liquid suspensions of the present invention provide benefits to pharmacies, pharmacists, doctors and patients having fungal infections.
Accordingly, the present invention provides a liquid suspension comprising micronized posaconazole, having the chemical structural formula I:
o H
F ~ F '~\\\ O NN N N (S) I N HS OH
(R) N~\-N
N
at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
This invention also provides a liquid suspension comprising an antifungally effective amount of micronized posaconazole having the chemical structural formula I:
BACKGROUND OF THE INVENTION
This invention relates to stable, liquid suspensions containing an antifungally effective amount of the micronized compound represented by the chemical structural formula I:
H& /\ N N \ ! N N S
N
HO
F R O
N
F ~=N
at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier, and methods of using the suspensions to treat or prevent fungal infections U.S. Patent No. 5,661,151 discloses the compound of formula I and its potent antifungal activity against a broad range of fungi such as Aspergillis, Candida, Cryptococcus, Fusarium, and other opportunistic fungi.
U.S. Patent Nos. 5,834,472 and 5,846,971, disclose oral pharmaceutical capsule compositions of the compound of structural formula I coated onto inert beads together with a binder. However, the compound of structural formula I is highly lipophilic, and has an extremely low water solubility. Thus, aqueous compositions of the compound of structural formula I were found to have reduced anti-fungal activity and/or bioavailability, presumably due to the extremely low water solubility of the compound. Accordingly, a need exists for an oral pharmaceutical composition of the compound of structural formula I that has enhanced bioavailability and improved stability characteristics SUMMARY OF THE INVENTION
We have found pharmaceutical compositions, in the form of liquid suspension, suitable for oral administration comprising micronized particles of posaconazole, the compound having the chemical structural formula I
F F H ~\\\O NN NN (S) N H\`, OH
(R) N-N
N
at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier that provides significant advantages over the prior art.
Advantages of the liquid suspensions of the present invention include improved homogeneity of the suspension and ease of dispersibility of the suspension. The solids that settle in the liquid suspension of the present invention do not form a solid cake that is difficult to re-disperse. There is virtually no sedimentation of the solids in the unreconstituted liquid suspension of this invention for a period of at least three days. This surprising feature ensures that a patient having a fungal infection taking the liquid suspensions of the present invention will receive an antifungally effective amount of posaconazole. The liquid suspensions of the present invention have a longer shelf life. Additionally, the liquid suspension, upon reconstitution, provide substantially the same antifungally effective amount posaconazole as the initially prepared suspension. These features of the liquid suspensions of the present invention provide benefits to pharmacies, pharmacists, doctors and patients having fungal infections.
Accordingly, the present invention provides a liquid suspension comprising micronized posaconazole, having the chemical structural formula I:
o H
F ~ F '~\\\ O NN N N (S) I N HS OH
(R) N~\-N
N
at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
This invention also provides a liquid suspension comprising an antifungally effective amount of micronized posaconazole having the chemical structural formula I:
H
F F O NN N N (S) S OH
(R) N
N-N
N
an effective amount of at least one thickening agent, an amount of a buffer system effective to maintain the pH of the system in the range of about 4.0 to about 6.0, an effective amount of a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
This invention further provides a liquid suspension comprising an antifungally effective amount of micronized posaconazole having the chemical structural formula I:
H O
F O~v F 0 N N NN (S) 3--- N H``OH
(R) N-N I
N
wherein the micronized compound has a mean particle size in the range of about 1200 nm to about 1600 nm, an effective amount of polyoxyethylene derivatives of sorbitan esters of saturated or unsaturated C12 to C18 acids, an effective amount of a buffer system sufficient to maintain a pH in the range of about 4.0 to about 6.0, an effective amount of a combination of two thickening agents, wherein one is a liquid sugar, and a pharmaceutically acceptable liquid carrier.
F F O NN N N (S) S OH
(R) N
N-N
N
an effective amount of at least one thickening agent, an amount of a buffer system effective to maintain the pH of the system in the range of about 4.0 to about 6.0, an effective amount of a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
This invention further provides a liquid suspension comprising an antifungally effective amount of micronized posaconazole having the chemical structural formula I:
H O
F O~v F 0 N N NN (S) 3--- N H``OH
(R) N-N I
N
wherein the micronized compound has a mean particle size in the range of about 1200 nm to about 1600 nm, an effective amount of polyoxyethylene derivatives of sorbitan esters of saturated or unsaturated C12 to C18 acids, an effective amount of a buffer system sufficient to maintain a pH in the range of about 4.0 to about 6.0, an effective amount of a combination of two thickening agents, wherein one is a liquid sugar, and a pharmaceutically acceptable liquid carrier.
5 In accordance with one aspect of the present invention there is provided a liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I:
F F H O NN N N (S) N H\`\7 S OH
(R) N - N
N
wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm, and a pharmaceutically acceptable liquid carrier.
In accordance with another aspect of the present invention there is provided a liquid suspension comprising:
= an antifungally effective amount of the micronized compound represented by the chemical structural formula I:
x F F H O NN N / \ N (S) N S OH
(R) N - N
N
5a = wherein the micronized compound of formula I has a mean particle size in the range of about 1000 nm to about 1800 nm;
= a polyoxyethylene derivative of sorbitan esters of saturated or unsaturated C12 to C18 acids;
= an effective amount of a buffer system sufficient to maintain a pH in the range of about 4.0 to about 6.0;
= a combination of two thickening agents, wherein one is a liquid sugar;
and a pharmaceutically acceptable liquid carrier.
In accordance with another aspect of the present invention there is provided a composition for at least one of treating and preventing a fungal infection in a patient, the composition in the form of a liquid, oral suspension comprising an antifungally effective amount of a micronized compound of the chemical structural formula I:
H O
F 6(R)N N NN (S) N S OH
N-N I
N
wherein the micronized compound of formula I has a mean particle size of 1000 nm to 1800 nm, and the composition comprises at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier, and is adapted to provide a maximum concentration (Cmax) of posaconazole in the plasma serum that is 2.5 to 4 times greater when administered with a high-fat meal or a non-fat meal as compared to when administered following a 10 hr fast.
5b In accordance with yet another aspect of the present invention there is provided a use of micronized particles of the compound of formula I
H O
F ..\\\O \ \/ /\ N~N (s) I v N H~\\\ S OH
(R) N-N I
\\N~
in the manufacture of a medicament in the form of a liquid, oral suspension for at least one of treating and preventing a fungal infection in a patient comprising an antifungally effective amount of the compound of formula I, wherein the medicament comprises at least one thickening agent, and least one, surfactant and a pharmaceutically acceptable liquid carrier, wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm.
BRIEF DESCRIPTION OF THE FIGURES
FIGS. I & 2 graphically display the mean plasma concentration time profiles of posaconazole tablets and of the liquid suspension of Example 1 of the present invention. FIG. 1 is a linear:linear graphic profile of the plasma concentration (ng/ml)of the compound of formula I versus time (hours) after administration of the following four Treatments A- D: a single of 2×100 mg of the compound of formula I in the tablet co-precipitate formulation of U.S.
Pat.
No. 5,834,472 with a standardized high-fat breakfast- Treatment D and.
Symbol -.-; a 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) following a 10-hr. fast -Treatment A and. symbol -O-;a 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) with a standardized high-fat breakfast-Treatment B and. symbol -d-;and a 200 mg of 5c the compound of formula I in the oral suspension of this invention (5 ml) with a standardized non-fat breakfast-Treatment C and. symbol-D-.
FIG. 2 is a log linear graphic profile of the plasma concentration (ng/ml)of the compound of formula I versus time in hours for the data presented in FIG.
1.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a stable suspension of micronized particles of the antifungal compound posaconazole in a pharmaceutically acceptable liquid carrier. The suspension of the present invention is stable to settling without sedimentation when stored undisturbed for more than three days at 25 C. (See Table 1 below).
Table 2 below shows that the liquid suspension formulations of this invention are stable in that the concentration of posaconazole in the suspension is substantially the same ( 2%) compared to the initial concentration (as measured by HPLC) for periods of up to 12 months.
We have also found that the stable suspension of the present invention has a remarkably higher (23-36% increase) bioavailability compared to an optimized io oral tablet of micronized particles of posaconazole when each is administered to subjects concurrently with a high fat breakfast. See Tables 3 and 4 and Figures 1 &2 One aspect of the present invention is to provide a pharmaceutical composition that contains micronized particles of posaconazole in combination with a non-ionic surfactant, such as a sorbitan ester and at least one thickening agent, preferably a combination of xanthan gum and a liquid sugar, that are easily dispersible in a pharmaceutically acceptable liquid carrier such as purified water.
The pharmaceutical composition provides a stabilized suspension that does not settle for at least three days, thus ensuring that patients will get an effective dose of posaconazole. Another feature of the stabilized suspension of the present invention is that it is useful in treating patients with HIV-1 infections with oral thrush without posaconazole precipitating out of solution. Another aspect of the present invention is that the suspension of the present invention avoids formation of solid cakes which are difficult to disperse.
The compound of formula I used in the suspensions of the present invention is available from Schering Corporation, Kenilworth, New Jersey , and has been prepared according to Examples 24 and 32 of U.S. Patent No. 5,661,151 and WO
95/17407.
Micron-sized particles of posaconazole preferably have a mean particle size range of about 1000 nanometers (nm) to about 1800 nm, preferably about 1200 nm to about 1600 nm, and most preferably about 1400 nm. This particle size can be io obtained either by the final step during the manufacture of the antifungal compound of formula I or by the use of conventional micronizing techniques after the conventional crystallization procedure(s).
The preferred micronizing technique that is employed to micronize the posaconazole to the desired mean particle size range is microfluidization.
Microfluidization is an alternative to traditional homogenization that utilizes the collision of two product streams at high pressures to produce a much more uniform particle size distribution (according to Microfluidics International Co.) and smaller average particle size of about 1200 nm to 1600 nm. The process and equipment used in microfluidization are described in U.S. Pat. No. 4,533,254.
The micronized posaconazole of the present invention may also be present in crystalline form. It is preferably substantially chemically and optically pure, and it contains less than about 10 % of its optical isomers, enantiomers or other diastereomers. It may be 99% of the optically pure the levorotatory or dextrarotatory isomer. This optically pure compound of chemical structure I
should avoid many of the untoward side effects of a mixture of other optical isomers.
Posaconazole liquid suspension is employed in the composition in antifungally amounts effective to control the fungi of interest. Such antifungally effective amounts can range from about 10 mg/ml to about 100 mg/ml concentration of the liquid suspension formulations of the present invention, more preferably from about 20 mg/ml to about 60 mg/ml, and most preferably about 40 mg/ml of the compound of formula I.
The present invention also provides for a method of treating and/or io preventing fungal infection in a mammal comprising administering to the mammal an amount of the liquid suspension containing the micronized posaconazole in an amount effective for treating and/or preventing such fungal infection.
Antifungally effective amounts of liquid suspensions of present invention containing 40 mg/ml of the compound of formula I is administered orally in the doses of 5 ml -containing 200 mg of formula I - three times a day (TID) or four times a day (QID)- or 10 ml-containing 400 mg of the compound of formula 1-twice a day (BID). Of course, the attending clinician may change the dose and dosing regimen in view of the age, health, and sex of the patient as well as the severity of the fungal infection.
The following terms are used to describe the present pharmaceutical compositions, ingredients that may be employed in its formulation and methods for assessing the compound's bioactivity or bioavailability.
Non-ionic surfactant refers to a surfactant which lacks a net ionic charge and does not dissociate to an appreciable extent in aqueous media. The properties of non-ionic surfactants are largely dependent upon the proportions of the hydrophilic and hydrophobic groups in the molecule. Hydrophilic groups include the oxyethylene group (-OCH2CH2-) and the hydroxy group. By varying the number of these groups in a hydrophobic molecule, such as an ester of a fatty acid, substances are obtained which range from strongly hydrophobic and water insoluble compounds, such as glyceryl monostearate, to strongly hydrophilic and water-soluble compounds, such as the macrogols. Between these two extremes types include those in which the proportions of the hydrophilic and hydrophobic groups are more evenly balanced, such as the macrogol esters and ethers and sorbitan derivatives. Suitable non-ionic surfactants may be found in Martindale, The io Extra Pharmacopoeia, 28th Edition, 1982, The Pharmaceutical Press, London, Great Britain, pp. 370 to 379.
Such suitable non-ionic surfactants include block copolymers of ethylene oxide and propylene oxide, glycol or glyceryl esters of saturated or unsaturated C8 to C20 acids, preferably, polyoxyethylene esters of saturated or unsaturated C8 to C20 acids, polyoxyethylene ethers of saturated or unsaturated C8to C20 acids, and polyvinyl alcohols or sorbitan esters of saturated or unsaturated C10 to C20 acids.
Preferably, the non-ionic surfactant is a sorbitan ester of a saturated or unsaturated C10 to C20 acid, and more preferably the sorbitan ester is a fatty acid ester of sorbitan selected from sorbitan monolaurate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, sorbitan monopalmitate, sorbitan monostearate and sorbitan tristearate, or mixtures thereof.
Suitable sorbitan esters include, e.g. Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 65, Polysorbate 80, Polysorbate 85, Sorbitan Monolaurate, Sorbitan Mono-oleate, Sorbitan Monopalmitate, Sorbitan Monostearate, Sorbitan Sesquioleate, Sorbitan Trioleate and Sorbitan Tristearate.
The most preferred non-ionic surfactant is Polysorbate 80, available from ICI
Americas under the tradename Tween 80 which is a mixture of oleate esters of sorbitol and sorbitol anhydrides, consisting predominantly of the monoester, 5 condensed with approximately 20 moles of ethylene oxide.
Suitable block copolymers of ethylene oxide and propylene oxide generically called "Poloxamers" and include those represented by the following chemical structure I:
HO(CH2CH2O)a(CH2CHO)b(CH2CH2O)aH
1o wherein a is an integer ranging from about 10 to about 110, preferably from about 12 to 101; more preferably from about 12 to 80; and b is an integer ranging from about 20 to about 60, more preferably from about 20 to about 56; also from about 20 to 27.
Suitable glycol and glyceryl esters of fatty acids include glyceryl monooleate 1s and similar water soluble derivatives;
Suitable polyoxyethylene esters of fatty acids (macrogol esters) include polyoxyethylene castor oil and hydrogenated castor oil derivatives;
Suitable polyoxyethylene ethers of fatty acids (macrogol ethers) include Cetomacrogel 1000, Lauromacrogols (a series of lauryl ethers of macrogols of differing chain lengths), e.g. Laureth 4, Laureth 9 and Lauromacrogol 400.
The effective amount of non-ionic surfactant in the composition can range from about 5 mg/ml to about 50 mg/ml concentration of the formulation, more preferably from about 5 mg/mI to about 25 mg/ml, and most preferably 10 mg/ml.
Thickening agents found suitable in the present invention include any commercially available agent useful for such purpose. Xanthan gum, liquid sugars, starches, celluloses and mixtures thereof are preferred thickening agents.
More preferred is a combination of xanthan gum and a liquid sugar and, most preferred is a combination of xanthan gum, NF and glucose, NF. Preferably, the xanthan gum is present in an amount of about 1 mg/ml to about 5 mg/ml, and more preferably the xanthan gum is present in an amount of about 3 mg/ml. Preferably, the glucose NF
is present in an amount of about 200 to about 500 mg/ml, and more preferably about 350 mg/ml. The effective amount of thickening agent of the present invention 1o may be about 1 to about 500 mg/ml, more preferably about 200 to about 500 mg/ml, most preferably about 353 mg/ml. The thickening agents of the present invention facilitate suspension of the formulation after constitution with minimum agitation and prevent rapid settling and caking of the suspension over time.
Pharmaceutically acceptable carriers include those well known in the art, including purified water USP, liquid glucose, NF, and anhydrous glycerol. Most preferred is purified water USP and liquid glucose, NF. The pharmaceutically acceptable carrier may be present in an amount of about 10 to about 500 mg/ml, more preferably about 200 mg/ml to about 400 mg/ml, most preferably about 350 mg/ml.
The buffer systems suitable for the formulations of the present invention are those which maintain the pH of the liquid suspension in the range of about 4 to about 6, preferably in the 4.5 to 5.0, and most preferably about 4.5. The use of a buffer system of sodium citrate, USP and citric acid, USP, is preferred. Other suitable buffer systems may be used to maintain the desired pH range of 4 to 6.
The buffering agents may be present in a concentration of about 0.4 to about 1.5 mg/ml, more preferably about 0.7 to about 1.5 mg/ml, most preferably about 1.1 mg/ml.
Anti-foaming agents found suitable in the present invention include any commercially available agent useful for such purpose including the methylated linear siloxsane polymers end blocked with trimethylsiloxyl units such as dimethicone and simethicone, as well as mixtures of dimethicone with an average chain length of 200 to 250 dimethylsiloxane units and silica gel. The effective amount of anti-foaming agents is an amount sufficient to provide a concentration of 1o about 2 mg/ml to about 4 mg/ml, preferably about 3 mg/ml.
The water soluble preservatives found useful in present invention include sodium benzoate, sodium citrate and benzalkonium chloride as well as other pharmaceutically acceptable water soluble preservatives. Use of sodium benzoate as a preservative is preferred. The effective amount of the water soluble preservative is an amount sufficient to provide a concentration of about 0.5 mg/ml to about 3 mg/ml, most preferably about 2 mg/ml.
The opacifier agents found suitable in the present invention include pharmaceutically acceptable metal oxides, especially titanium dioxide. The effective amount of the opacifier agent is an amount sufficient to provide a concentration of about 2 mg/ml to about 6 mg/ml, most preferably about 4 mg/ml.
Typical flavoring agents are those that are approved by FDA for use in sweetened pharmaceuticals, foods, candies, beverages and the like; these materials impart flavors such as grape, cherry, citrus, peach, strawberry, bubble gum, peppermint and many others. The effective amount of the flavoring agents is an amount sufficient to provide a concentration of about 0.01 mg/ml to about 6 mg/ml, more preferably about 5 mg/ml.
The following examples describe compositions of the present invention containing posaconazole, but they are not to be interpreted as limiting the scope of the claims.
Ingredient Concentration Range (mg/ml) Posaconazole (micronized) 10-100 Polysorbate 80 5-50 Sodium Citrate, USP, 0.4-0.8 Monohydrate Citric Acid, USP, Monohydrate 0.36-0.6 Simethicone, USP 2-4 Xanthan Gum, NF 1-5 Sodium Benzoate, NF 0.5-3 Liquid Glucose, NF 200-500 Glycerin, USP 50-150 Artificial Cherry Flavor 2-10 Titanium Dioxide 2-6 Purified Water, USP q.s. ad ---The above ranges of ingredients may be varied as is evident to one skilled in the art.
Specific examples of a composition within the scope of the invention is set forth below.
Example 1 Ingredient Concentration (mg/ml) Posaconazole 40 (micronized) Polysorbate 80 10 Sodium Citrate, USP, 0.6 Monohydrate Citric Acid, USP, 0.48 Monohydrate Simethicone, USP 3 Xanthan Gum, NF 3 Sodium Benzoate, NF 2 Liquid Glucose, NF 350 Glycerin, USP 100 Artificial Cherry Flavor 5 Titanium Dioxide 4 Purified Water, USP q.s. 1 ml ad This example is prepared as follows: charge approximately 5% of the final batch volume of purified water at 20 3 C to a suitable vessel equipped with a mixer propeller. Add 40% of the polysorbate 80 to the purified water in step 1 and mix until dissolved. Add 40% of the simethicone and mix until it is dispersed.
5 Recirculate the mixture in step 3 through a Microfluidizer, operating at about 30,000 5000 psi for approximately 5 passes. Add approximately 7% of the final batch volume of purified water at about 20 3 C, and mix for approximately five minutes.
Add the Posaconazole to the vessel in step 5 with constant mixing. Continue mixing until it is fully dispersed. Recirculate the suspension portion from step 6 1o through a Microfluidizer, operating at a pressure of about 30,000 5,000 psi.
Process the concentrate until the median of the particles shows a particle size of about 1.4 0.2 pm, when measured via laser diffraction techniques that are known in the art.
When the particle size has been achieved, pass the suspension through the 15 microfluidizer and collect in a suitable sized vessel. Add approximately 8-10% of the final batch volume of purified water (at 20 3 C) to the feed vessel, and pass through the microfluidizer operating at approximately 30,000 psi. Collect the rinse in the vessel containing the concentrate. Add approximately 22% of the final batch volume of purified water (20 3 C) to the vessel with the concentrate, and mix for approximately five (5) minutes. Add the remainder of the polysorbate 80 and simethicone, and mix for approximately five (5) minutes.
Add the sodium benzoate, sodium citrate and citric acid and mix for approximately five (5) minutes. Add the xanthan gum slowly with constant mixing.
Continue to mix after addition of the xanthan gum. Allow the xanthan gum to hydrate without mixing for 30 minutes. Add the glycerin with constant mixing.
Add the liquid glucose slowly with constant mixing. Mix for five minutes or until it is dissolved. Add the titanium dioxide and mix using a suitable homogenizer until that ingredient is fully dispersed. Add the artificial cherry flavor, and mix for approximately five minutes. Add purified water at 20 3 C, and qs up to a final volume, and mix until a uniform suspension is attained. Collect approximately 20 ml sample for pH measurement and physical observation of the suspension. The pH
of the suspension of Example 1 was 5Ø
Example 2 Example 2 is another example of a formulation within the scope of the present invention prepared using the procedure of Example 1 and has a pH of 4.5.
Ingredient Concentration (mg/ml) Posaconazole (micronized) 40 Polysorbate 80 10 Sodium Citrate, USP, 0.6 Monohydrate Citric Acid, USP, Monohydrate 1.5 Simethicone, USP 3 Xanthan Gum, NF 3 Sodium Benzoate, NF 2 Liquid Glucose, NF 350 Glycerin, USP 100 Artificial Cherry Flavor 5 Titanium Dioxide 4 Purified Water, USP q.s. ad 1 ml The rate of sedimentation of the liquid suspension of the present invention was determined as set forth below.
Posaconazole Oral Suspension 40 mg/ml Rate of Sedimentation Sodium Bottle Posaconazole % Label Benzoate % Label Number Time mg/ml Strength mg/mi Strength 1 0 min 39.9 99.8 2.00 100 1 5 min 40.0 100 1.99 99.5 1 10 min 40.0 100 2.00 100 1 30 min 40.0 100 2.00 100 1 60 min 40.2 101 2.01 101 1 3 days 40.2 101 2.02 101 2 0 min 39.8 99.5 2.01 101 2 5 min 39.9 99.8 2.00 100 2 10 min 40.2 101 2.01 101 2 30 min 39.8 99.5 1.99 99.5 2 60 min 40.2 101 2.02 101 2 3 days 40.1 100 2.01 101 Two bottles containing the suspension of the present invention were shaken 1o and left to rest. The bottles were then sampled immediately (time zero), then after 5 minutes, 10 minutes, 30 minutes, 60 minutes and after 72 hours (three days) post shaking. The levels of posaconazole and of the preservative (Sodium Benzoate) in these samples were assayed by HPLC. HPLC methods of detection are well-known to one of skill in the art.
The results of the assay of the preservative and of the posaconazole remained consistent and did not change. These ranged from 39.8 to 40.2 mg/ml (99.5 to 101 %) for the active and 1.99 to 2.02 mg/m: (99.5 to 101 %) for the preservative, respectively. The results of this experiment are shown in Table above.
The sodium benzoate was not expected to sediment. Surprisingly, the posaconazole was not sedimented after 3 days.
Thus, the compositions of the present invention have both ease of dispersibility and homogeneity as is evidenced by the stability of the samples in to Table 1.
Next, accelerated homogeneity testing was performed on the liquid suspension of the present invention.
Posaconazole Oral Suspension 40 mg/ml Homogeneity Accelerated Posaconazole Sodium Benzoate Condition Time point % Label Strength % Label Strength Initial Initial 103;102;104 105;102;103 30 H (30 C/60%RH) 3 Months 103;105;104 103;107;105 RH4 (40 C/75%RH) 3 Months 102;104;103 104;106;106 30 H 6 Months 102;101;102 103;101;102 RH4 6 Months 102;102;102 101;101;102 H 12 Months 104;104;104 101;100;100 25 H 24 Months 104;104;104 101;101;101 * Shaking and receiving the dose as per patient instruction.
These data (sedimentation rate experiment) were in agreement with the real 20 time stability data (up to 6 months at 40 C/75%RH and up to 24 months at 25 C/60%RH) that are shown in Table 2. The assay homogeneity results, surprisingly, remained consistently homogenous and practically unchanged.
After 6 months at 40 C/75%RH the homogeneity results ranged from 40.7 to 40.8 mg/mI (101 %) for the active and 2.01 to 2.03 mg/ml (101 to 102%) for preservative, respectively. These results were obtained regardless of the portion of the bottle assayed, i.e., top, or bottom of the bottle. Therefore, it can be concluded that the suspension was homogenous throughout the bottle even after relatively long exposure to accelerated stability conditions.
After 24 months at 25 C/60%RH the homogeneity results ranged from 41.5 1o to 41.6 mg/ml (104%) for the active and 2.01 mg/ml (101 %) for the preservative, respectively. These results were obtained regardless of the portion of the bottle assayed, i.e., top or bottom of the bottle. Therefore, it can be concluded that the suspension was homogenous throughout the bottle even after long term (24 months) exposure to 25 C/60%RH.
Bioavailability is defined as the rate and extent to that the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.
Cmax value is defined as the maximum concentration of the antifungal compound measured (i.e. "peak") in the plasma serum.
Formulations of the present invention have the advantage that they have an increased bioavailability and lower variability than previous formulations.
The relative bioavailability of the posaconazole oral suspension was compared to a solid dosage form of posaconazole in healthy subjects.
The first objective was to determine the relative bioavailability of posaconazole given as an oral suspension compared to an oral solid formulation when administered with a high-fat breakfast. The second objective was to determine the effect of high-fat and non-fat food relative to fasting conditions on the 5 oral bioavailability of the compound of formula I when given as an oral suspension.
Twenty healthy subjects completed this randomized, open-label, 4-way crossover, single-dose bioavailability and food effect study of posaconazole.
Subjects received each of the following four treatments separated by at least a 7 day washout period:
Treatment A: 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) following a 10-hr.
fast Treatment B: 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) with a standardized high-fat breakfast Treatment C: 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) with a standardized non-fat breakfast Treatment D: 2 x 100 mg of the compound of formula I in the tablets (co-precipitate formulation of U.S. Patent No. 5,834,472 with a standardized high-fat breakfast Subjects were randomized to either remain fasted (Treatment A), to receive a standardized high fat breakfast (Treatment B or D) or a standardized non-fat breakfast (Treatment C). Meals were consumed in a 20-minute period prior to the morning drug administration and subjects received the appropriate treatment within 5 minute of completing the breakfast.
Blood samples (6 ml) were collected into heparinized tubes for each treatment immediately prior to dosing (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after dosing. Blood was centrifuged at 4 C and plasma stored at or below -20 C until assayed. Plasma concentrations of posaconazole were assayed using a validated high performance liquid chromatographic assay with a LOQ of ng/ml.
Individual plasma concentration-time data were used for pharmacokinetic analysis using model-independent methods. The maximum concentration (Cmax) and time of maximum concentration (Tmax) were the observed values. The area to under the plasma concentration-time curve from time zero to the final quantifiable sampling time [AUC(tf)] was calculated using the linear trapezoidal method and extrapolated to infinity (I) as follows:
C(tf) AUC(I) = AUC(tf) K
where C(tf) is the estimated concentration determined from linear regression at time, tf.
Total body clearance was calculated by the following:
CL =Dose/ AUC(I) The apparent volume of distribution (Vdarea/F) was calculated from the ratio of the total body clearance to the terminal phase rate constant (K).
Summary statistics were calculated for the plasma suspension formulation of the present invention compared to a prior art tablet formulation concentration-time data at each time point and the derived pharmacokinetic parameters. The original scale and log-transformed Cmax and AUC values were analyzed using an analysis of variance (ANOVA). The effects due to subject, phase and treatment were extracted.
The plasma concentration-time data and pharmacokinetic parameters for the compound of formula I are tabulated in Tables 3 & 4 and depicted graphically in Figures 1 & 2.
All subjects had 0-hour concentrations on Day 1 reported as below the LOQ
(5 ng/ml) except for Subject 20 in Phases 3 and 4 who had quantifiable levels of posaconazole at 0-hour for Treatments B and A of 8.5 and 22.5 ng/ml, respectively.
io These levels are most likely due to a carry-over effect from accumulation from previous doses.
A summary of the meana pharmacokinetic parameters are provided in the table below:
Table 3 Tablet Suspension High Fat D 10 hr Fast A High Fat B Non-Fat C
Parameter Unit Mean %CV Mean %CV Mean %CV Mean %CV
Cmax ng/ml 413 33 132 50 512 34 378 43 Tmax Hr 5.5 32 5.01 49 4.8 9 4.1 21 AUC(tf) ng-hr/ml 10304 41 3553 36 13885 41 9511 38 AUC(I) ng-hr/ml 11832 39 4179 31 15059 26 10753 35 t%2 hr 21.0 15 23.5 25 23.0 19 22.2 18 a: Balanced means, n=20 except for AUC(I) and t'/2, n=1 5.
Posaconazole was slowly absorbed; the mean Tmax values ranged from 4.1 to 5.5 hr. Posaconazole was slowly eliminated with a mean terminal t1/2 of about 22 hour which was independent of treatment. This study was conducted to evaluate the bioavailability of posaconazole oral suspension (Treatment B) compared to a tablet formulation (Treatment D), both given with a high-fat food. The results, based on log-transformed data, are shown below:
Table 4 Treatments Relative 90%
Given After Bioavailability Confidence High Fat Geometric b Interval Parameter Breakfast Mean (%) Cmax Suspension 485 ng/ml 123.3 104-146 Tablet 394 ng/ml a Suspension 13141 ng.hr/ml 136.5 119-156 AUC(tf) Tablet 9624 ng.hr/ml a: AUC(tf) was used for statistical comparisons because it could be calculated for all treatments for all subjects.
b: Suspension relative to tablet.
On average, the suspension formulation of the present invention resulted in 1o a 23% increase in Cmax and a 36% increase in AUC(tf) compared to the tablet of the prior art.
The secondary objective of the study was to evaluate the effect of high fat food (Treatment B) and non-fat food (Treatment C) compared to fasting (Treatment A) on the oral bioavailability of posaconazole administered as an oral suspension.
The results, based on log-transformed data, are shown below:
Table 5 Relative Bioavailability 90%
Suspension Geometric a Confidence Parameter Treatments Mean (%) Interval Cmax High-Fat 485 417 352-493 (ng/ml) Non-Fat 345 296 250-350 Fast 116 -- --AUC(tf) High-Fat 13141 392 343-448 (ng.hr/ml Non-Fat 8857 264 231-302 Fast 3352 -- --a: Expressed as a percent of Treatment A - Suspension/Fast.
A high fat breakfast produced a 4-fold increase in the bioavailability of posaconazole given in a suspension. This was consistent with results from a previous study where food significantly increased the bioavailability of posaconazole by 3-5-fold for both tablet and capsule formulations. The effect of a non-fat breakfast (Treatment C) compared to fasting (Treatment A) was less, with a 2.5-3-fold increase in bioavailability.
Many modifications and variations of this invention can be made without io departing from its spirit and scope, as will be apparent to one skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims along with the full scope of equivalents to which such claims are entitled.
F F H O NN N N (S) N H\`\7 S OH
(R) N - N
N
wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm, and a pharmaceutically acceptable liquid carrier.
In accordance with another aspect of the present invention there is provided a liquid suspension comprising:
= an antifungally effective amount of the micronized compound represented by the chemical structural formula I:
x F F H O NN N / \ N (S) N S OH
(R) N - N
N
5a = wherein the micronized compound of formula I has a mean particle size in the range of about 1000 nm to about 1800 nm;
= a polyoxyethylene derivative of sorbitan esters of saturated or unsaturated C12 to C18 acids;
= an effective amount of a buffer system sufficient to maintain a pH in the range of about 4.0 to about 6.0;
= a combination of two thickening agents, wherein one is a liquid sugar;
and a pharmaceutically acceptable liquid carrier.
In accordance with another aspect of the present invention there is provided a composition for at least one of treating and preventing a fungal infection in a patient, the composition in the form of a liquid, oral suspension comprising an antifungally effective amount of a micronized compound of the chemical structural formula I:
H O
F 6(R)N N NN (S) N S OH
N-N I
N
wherein the micronized compound of formula I has a mean particle size of 1000 nm to 1800 nm, and the composition comprises at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier, and is adapted to provide a maximum concentration (Cmax) of posaconazole in the plasma serum that is 2.5 to 4 times greater when administered with a high-fat meal or a non-fat meal as compared to when administered following a 10 hr fast.
5b In accordance with yet another aspect of the present invention there is provided a use of micronized particles of the compound of formula I
H O
F ..\\\O \ \/ /\ N~N (s) I v N H~\\\ S OH
(R) N-N I
\\N~
in the manufacture of a medicament in the form of a liquid, oral suspension for at least one of treating and preventing a fungal infection in a patient comprising an antifungally effective amount of the compound of formula I, wherein the medicament comprises at least one thickening agent, and least one, surfactant and a pharmaceutically acceptable liquid carrier, wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm.
BRIEF DESCRIPTION OF THE FIGURES
FIGS. I & 2 graphically display the mean plasma concentration time profiles of posaconazole tablets and of the liquid suspension of Example 1 of the present invention. FIG. 1 is a linear:linear graphic profile of the plasma concentration (ng/ml)of the compound of formula I versus time (hours) after administration of the following four Treatments A- D: a single of 2×100 mg of the compound of formula I in the tablet co-precipitate formulation of U.S.
Pat.
No. 5,834,472 with a standardized high-fat breakfast- Treatment D and.
Symbol -.-; a 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) following a 10-hr. fast -Treatment A and. symbol -O-;a 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) with a standardized high-fat breakfast-Treatment B and. symbol -d-;and a 200 mg of 5c the compound of formula I in the oral suspension of this invention (5 ml) with a standardized non-fat breakfast-Treatment C and. symbol-D-.
FIG. 2 is a log linear graphic profile of the plasma concentration (ng/ml)of the compound of formula I versus time in hours for the data presented in FIG.
1.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a stable suspension of micronized particles of the antifungal compound posaconazole in a pharmaceutically acceptable liquid carrier. The suspension of the present invention is stable to settling without sedimentation when stored undisturbed for more than three days at 25 C. (See Table 1 below).
Table 2 below shows that the liquid suspension formulations of this invention are stable in that the concentration of posaconazole in the suspension is substantially the same ( 2%) compared to the initial concentration (as measured by HPLC) for periods of up to 12 months.
We have also found that the stable suspension of the present invention has a remarkably higher (23-36% increase) bioavailability compared to an optimized io oral tablet of micronized particles of posaconazole when each is administered to subjects concurrently with a high fat breakfast. See Tables 3 and 4 and Figures 1 &2 One aspect of the present invention is to provide a pharmaceutical composition that contains micronized particles of posaconazole in combination with a non-ionic surfactant, such as a sorbitan ester and at least one thickening agent, preferably a combination of xanthan gum and a liquid sugar, that are easily dispersible in a pharmaceutically acceptable liquid carrier such as purified water.
The pharmaceutical composition provides a stabilized suspension that does not settle for at least three days, thus ensuring that patients will get an effective dose of posaconazole. Another feature of the stabilized suspension of the present invention is that it is useful in treating patients with HIV-1 infections with oral thrush without posaconazole precipitating out of solution. Another aspect of the present invention is that the suspension of the present invention avoids formation of solid cakes which are difficult to disperse.
The compound of formula I used in the suspensions of the present invention is available from Schering Corporation, Kenilworth, New Jersey , and has been prepared according to Examples 24 and 32 of U.S. Patent No. 5,661,151 and WO
95/17407.
Micron-sized particles of posaconazole preferably have a mean particle size range of about 1000 nanometers (nm) to about 1800 nm, preferably about 1200 nm to about 1600 nm, and most preferably about 1400 nm. This particle size can be io obtained either by the final step during the manufacture of the antifungal compound of formula I or by the use of conventional micronizing techniques after the conventional crystallization procedure(s).
The preferred micronizing technique that is employed to micronize the posaconazole to the desired mean particle size range is microfluidization.
Microfluidization is an alternative to traditional homogenization that utilizes the collision of two product streams at high pressures to produce a much more uniform particle size distribution (according to Microfluidics International Co.) and smaller average particle size of about 1200 nm to 1600 nm. The process and equipment used in microfluidization are described in U.S. Pat. No. 4,533,254.
The micronized posaconazole of the present invention may also be present in crystalline form. It is preferably substantially chemically and optically pure, and it contains less than about 10 % of its optical isomers, enantiomers or other diastereomers. It may be 99% of the optically pure the levorotatory or dextrarotatory isomer. This optically pure compound of chemical structure I
should avoid many of the untoward side effects of a mixture of other optical isomers.
Posaconazole liquid suspension is employed in the composition in antifungally amounts effective to control the fungi of interest. Such antifungally effective amounts can range from about 10 mg/ml to about 100 mg/ml concentration of the liquid suspension formulations of the present invention, more preferably from about 20 mg/ml to about 60 mg/ml, and most preferably about 40 mg/ml of the compound of formula I.
The present invention also provides for a method of treating and/or io preventing fungal infection in a mammal comprising administering to the mammal an amount of the liquid suspension containing the micronized posaconazole in an amount effective for treating and/or preventing such fungal infection.
Antifungally effective amounts of liquid suspensions of present invention containing 40 mg/ml of the compound of formula I is administered orally in the doses of 5 ml -containing 200 mg of formula I - three times a day (TID) or four times a day (QID)- or 10 ml-containing 400 mg of the compound of formula 1-twice a day (BID). Of course, the attending clinician may change the dose and dosing regimen in view of the age, health, and sex of the patient as well as the severity of the fungal infection.
The following terms are used to describe the present pharmaceutical compositions, ingredients that may be employed in its formulation and methods for assessing the compound's bioactivity or bioavailability.
Non-ionic surfactant refers to a surfactant which lacks a net ionic charge and does not dissociate to an appreciable extent in aqueous media. The properties of non-ionic surfactants are largely dependent upon the proportions of the hydrophilic and hydrophobic groups in the molecule. Hydrophilic groups include the oxyethylene group (-OCH2CH2-) and the hydroxy group. By varying the number of these groups in a hydrophobic molecule, such as an ester of a fatty acid, substances are obtained which range from strongly hydrophobic and water insoluble compounds, such as glyceryl monostearate, to strongly hydrophilic and water-soluble compounds, such as the macrogols. Between these two extremes types include those in which the proportions of the hydrophilic and hydrophobic groups are more evenly balanced, such as the macrogol esters and ethers and sorbitan derivatives. Suitable non-ionic surfactants may be found in Martindale, The io Extra Pharmacopoeia, 28th Edition, 1982, The Pharmaceutical Press, London, Great Britain, pp. 370 to 379.
Such suitable non-ionic surfactants include block copolymers of ethylene oxide and propylene oxide, glycol or glyceryl esters of saturated or unsaturated C8 to C20 acids, preferably, polyoxyethylene esters of saturated or unsaturated C8 to C20 acids, polyoxyethylene ethers of saturated or unsaturated C8to C20 acids, and polyvinyl alcohols or sorbitan esters of saturated or unsaturated C10 to C20 acids.
Preferably, the non-ionic surfactant is a sorbitan ester of a saturated or unsaturated C10 to C20 acid, and more preferably the sorbitan ester is a fatty acid ester of sorbitan selected from sorbitan monolaurate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, sorbitan monopalmitate, sorbitan monostearate and sorbitan tristearate, or mixtures thereof.
Suitable sorbitan esters include, e.g. Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 65, Polysorbate 80, Polysorbate 85, Sorbitan Monolaurate, Sorbitan Mono-oleate, Sorbitan Monopalmitate, Sorbitan Monostearate, Sorbitan Sesquioleate, Sorbitan Trioleate and Sorbitan Tristearate.
The most preferred non-ionic surfactant is Polysorbate 80, available from ICI
Americas under the tradename Tween 80 which is a mixture of oleate esters of sorbitol and sorbitol anhydrides, consisting predominantly of the monoester, 5 condensed with approximately 20 moles of ethylene oxide.
Suitable block copolymers of ethylene oxide and propylene oxide generically called "Poloxamers" and include those represented by the following chemical structure I:
HO(CH2CH2O)a(CH2CHO)b(CH2CH2O)aH
1o wherein a is an integer ranging from about 10 to about 110, preferably from about 12 to 101; more preferably from about 12 to 80; and b is an integer ranging from about 20 to about 60, more preferably from about 20 to about 56; also from about 20 to 27.
Suitable glycol and glyceryl esters of fatty acids include glyceryl monooleate 1s and similar water soluble derivatives;
Suitable polyoxyethylene esters of fatty acids (macrogol esters) include polyoxyethylene castor oil and hydrogenated castor oil derivatives;
Suitable polyoxyethylene ethers of fatty acids (macrogol ethers) include Cetomacrogel 1000, Lauromacrogols (a series of lauryl ethers of macrogols of differing chain lengths), e.g. Laureth 4, Laureth 9 and Lauromacrogol 400.
The effective amount of non-ionic surfactant in the composition can range from about 5 mg/ml to about 50 mg/ml concentration of the formulation, more preferably from about 5 mg/mI to about 25 mg/ml, and most preferably 10 mg/ml.
Thickening agents found suitable in the present invention include any commercially available agent useful for such purpose. Xanthan gum, liquid sugars, starches, celluloses and mixtures thereof are preferred thickening agents.
More preferred is a combination of xanthan gum and a liquid sugar and, most preferred is a combination of xanthan gum, NF and glucose, NF. Preferably, the xanthan gum is present in an amount of about 1 mg/ml to about 5 mg/ml, and more preferably the xanthan gum is present in an amount of about 3 mg/ml. Preferably, the glucose NF
is present in an amount of about 200 to about 500 mg/ml, and more preferably about 350 mg/ml. The effective amount of thickening agent of the present invention 1o may be about 1 to about 500 mg/ml, more preferably about 200 to about 500 mg/ml, most preferably about 353 mg/ml. The thickening agents of the present invention facilitate suspension of the formulation after constitution with minimum agitation and prevent rapid settling and caking of the suspension over time.
Pharmaceutically acceptable carriers include those well known in the art, including purified water USP, liquid glucose, NF, and anhydrous glycerol. Most preferred is purified water USP and liquid glucose, NF. The pharmaceutically acceptable carrier may be present in an amount of about 10 to about 500 mg/ml, more preferably about 200 mg/ml to about 400 mg/ml, most preferably about 350 mg/ml.
The buffer systems suitable for the formulations of the present invention are those which maintain the pH of the liquid suspension in the range of about 4 to about 6, preferably in the 4.5 to 5.0, and most preferably about 4.5. The use of a buffer system of sodium citrate, USP and citric acid, USP, is preferred. Other suitable buffer systems may be used to maintain the desired pH range of 4 to 6.
The buffering agents may be present in a concentration of about 0.4 to about 1.5 mg/ml, more preferably about 0.7 to about 1.5 mg/ml, most preferably about 1.1 mg/ml.
Anti-foaming agents found suitable in the present invention include any commercially available agent useful for such purpose including the methylated linear siloxsane polymers end blocked with trimethylsiloxyl units such as dimethicone and simethicone, as well as mixtures of dimethicone with an average chain length of 200 to 250 dimethylsiloxane units and silica gel. The effective amount of anti-foaming agents is an amount sufficient to provide a concentration of 1o about 2 mg/ml to about 4 mg/ml, preferably about 3 mg/ml.
The water soluble preservatives found useful in present invention include sodium benzoate, sodium citrate and benzalkonium chloride as well as other pharmaceutically acceptable water soluble preservatives. Use of sodium benzoate as a preservative is preferred. The effective amount of the water soluble preservative is an amount sufficient to provide a concentration of about 0.5 mg/ml to about 3 mg/ml, most preferably about 2 mg/ml.
The opacifier agents found suitable in the present invention include pharmaceutically acceptable metal oxides, especially titanium dioxide. The effective amount of the opacifier agent is an amount sufficient to provide a concentration of about 2 mg/ml to about 6 mg/ml, most preferably about 4 mg/ml.
Typical flavoring agents are those that are approved by FDA for use in sweetened pharmaceuticals, foods, candies, beverages and the like; these materials impart flavors such as grape, cherry, citrus, peach, strawberry, bubble gum, peppermint and many others. The effective amount of the flavoring agents is an amount sufficient to provide a concentration of about 0.01 mg/ml to about 6 mg/ml, more preferably about 5 mg/ml.
The following examples describe compositions of the present invention containing posaconazole, but they are not to be interpreted as limiting the scope of the claims.
Ingredient Concentration Range (mg/ml) Posaconazole (micronized) 10-100 Polysorbate 80 5-50 Sodium Citrate, USP, 0.4-0.8 Monohydrate Citric Acid, USP, Monohydrate 0.36-0.6 Simethicone, USP 2-4 Xanthan Gum, NF 1-5 Sodium Benzoate, NF 0.5-3 Liquid Glucose, NF 200-500 Glycerin, USP 50-150 Artificial Cherry Flavor 2-10 Titanium Dioxide 2-6 Purified Water, USP q.s. ad ---The above ranges of ingredients may be varied as is evident to one skilled in the art.
Specific examples of a composition within the scope of the invention is set forth below.
Example 1 Ingredient Concentration (mg/ml) Posaconazole 40 (micronized) Polysorbate 80 10 Sodium Citrate, USP, 0.6 Monohydrate Citric Acid, USP, 0.48 Monohydrate Simethicone, USP 3 Xanthan Gum, NF 3 Sodium Benzoate, NF 2 Liquid Glucose, NF 350 Glycerin, USP 100 Artificial Cherry Flavor 5 Titanium Dioxide 4 Purified Water, USP q.s. 1 ml ad This example is prepared as follows: charge approximately 5% of the final batch volume of purified water at 20 3 C to a suitable vessel equipped with a mixer propeller. Add 40% of the polysorbate 80 to the purified water in step 1 and mix until dissolved. Add 40% of the simethicone and mix until it is dispersed.
5 Recirculate the mixture in step 3 through a Microfluidizer, operating at about 30,000 5000 psi for approximately 5 passes. Add approximately 7% of the final batch volume of purified water at about 20 3 C, and mix for approximately five minutes.
Add the Posaconazole to the vessel in step 5 with constant mixing. Continue mixing until it is fully dispersed. Recirculate the suspension portion from step 6 1o through a Microfluidizer, operating at a pressure of about 30,000 5,000 psi.
Process the concentrate until the median of the particles shows a particle size of about 1.4 0.2 pm, when measured via laser diffraction techniques that are known in the art.
When the particle size has been achieved, pass the suspension through the 15 microfluidizer and collect in a suitable sized vessel. Add approximately 8-10% of the final batch volume of purified water (at 20 3 C) to the feed vessel, and pass through the microfluidizer operating at approximately 30,000 psi. Collect the rinse in the vessel containing the concentrate. Add approximately 22% of the final batch volume of purified water (20 3 C) to the vessel with the concentrate, and mix for approximately five (5) minutes. Add the remainder of the polysorbate 80 and simethicone, and mix for approximately five (5) minutes.
Add the sodium benzoate, sodium citrate and citric acid and mix for approximately five (5) minutes. Add the xanthan gum slowly with constant mixing.
Continue to mix after addition of the xanthan gum. Allow the xanthan gum to hydrate without mixing for 30 minutes. Add the glycerin with constant mixing.
Add the liquid glucose slowly with constant mixing. Mix for five minutes or until it is dissolved. Add the titanium dioxide and mix using a suitable homogenizer until that ingredient is fully dispersed. Add the artificial cherry flavor, and mix for approximately five minutes. Add purified water at 20 3 C, and qs up to a final volume, and mix until a uniform suspension is attained. Collect approximately 20 ml sample for pH measurement and physical observation of the suspension. The pH
of the suspension of Example 1 was 5Ø
Example 2 Example 2 is another example of a formulation within the scope of the present invention prepared using the procedure of Example 1 and has a pH of 4.5.
Ingredient Concentration (mg/ml) Posaconazole (micronized) 40 Polysorbate 80 10 Sodium Citrate, USP, 0.6 Monohydrate Citric Acid, USP, Monohydrate 1.5 Simethicone, USP 3 Xanthan Gum, NF 3 Sodium Benzoate, NF 2 Liquid Glucose, NF 350 Glycerin, USP 100 Artificial Cherry Flavor 5 Titanium Dioxide 4 Purified Water, USP q.s. ad 1 ml The rate of sedimentation of the liquid suspension of the present invention was determined as set forth below.
Posaconazole Oral Suspension 40 mg/ml Rate of Sedimentation Sodium Bottle Posaconazole % Label Benzoate % Label Number Time mg/ml Strength mg/mi Strength 1 0 min 39.9 99.8 2.00 100 1 5 min 40.0 100 1.99 99.5 1 10 min 40.0 100 2.00 100 1 30 min 40.0 100 2.00 100 1 60 min 40.2 101 2.01 101 1 3 days 40.2 101 2.02 101 2 0 min 39.8 99.5 2.01 101 2 5 min 39.9 99.8 2.00 100 2 10 min 40.2 101 2.01 101 2 30 min 39.8 99.5 1.99 99.5 2 60 min 40.2 101 2.02 101 2 3 days 40.1 100 2.01 101 Two bottles containing the suspension of the present invention were shaken 1o and left to rest. The bottles were then sampled immediately (time zero), then after 5 minutes, 10 minutes, 30 minutes, 60 minutes and after 72 hours (three days) post shaking. The levels of posaconazole and of the preservative (Sodium Benzoate) in these samples were assayed by HPLC. HPLC methods of detection are well-known to one of skill in the art.
The results of the assay of the preservative and of the posaconazole remained consistent and did not change. These ranged from 39.8 to 40.2 mg/ml (99.5 to 101 %) for the active and 1.99 to 2.02 mg/m: (99.5 to 101 %) for the preservative, respectively. The results of this experiment are shown in Table above.
The sodium benzoate was not expected to sediment. Surprisingly, the posaconazole was not sedimented after 3 days.
Thus, the compositions of the present invention have both ease of dispersibility and homogeneity as is evidenced by the stability of the samples in to Table 1.
Next, accelerated homogeneity testing was performed on the liquid suspension of the present invention.
Posaconazole Oral Suspension 40 mg/ml Homogeneity Accelerated Posaconazole Sodium Benzoate Condition Time point % Label Strength % Label Strength Initial Initial 103;102;104 105;102;103 30 H (30 C/60%RH) 3 Months 103;105;104 103;107;105 RH4 (40 C/75%RH) 3 Months 102;104;103 104;106;106 30 H 6 Months 102;101;102 103;101;102 RH4 6 Months 102;102;102 101;101;102 H 12 Months 104;104;104 101;100;100 25 H 24 Months 104;104;104 101;101;101 * Shaking and receiving the dose as per patient instruction.
These data (sedimentation rate experiment) were in agreement with the real 20 time stability data (up to 6 months at 40 C/75%RH and up to 24 months at 25 C/60%RH) that are shown in Table 2. The assay homogeneity results, surprisingly, remained consistently homogenous and practically unchanged.
After 6 months at 40 C/75%RH the homogeneity results ranged from 40.7 to 40.8 mg/mI (101 %) for the active and 2.01 to 2.03 mg/ml (101 to 102%) for preservative, respectively. These results were obtained regardless of the portion of the bottle assayed, i.e., top, or bottom of the bottle. Therefore, it can be concluded that the suspension was homogenous throughout the bottle even after relatively long exposure to accelerated stability conditions.
After 24 months at 25 C/60%RH the homogeneity results ranged from 41.5 1o to 41.6 mg/ml (104%) for the active and 2.01 mg/ml (101 %) for the preservative, respectively. These results were obtained regardless of the portion of the bottle assayed, i.e., top or bottom of the bottle. Therefore, it can be concluded that the suspension was homogenous throughout the bottle even after long term (24 months) exposure to 25 C/60%RH.
Bioavailability is defined as the rate and extent to that the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.
Cmax value is defined as the maximum concentration of the antifungal compound measured (i.e. "peak") in the plasma serum.
Formulations of the present invention have the advantage that they have an increased bioavailability and lower variability than previous formulations.
The relative bioavailability of the posaconazole oral suspension was compared to a solid dosage form of posaconazole in healthy subjects.
The first objective was to determine the relative bioavailability of posaconazole given as an oral suspension compared to an oral solid formulation when administered with a high-fat breakfast. The second objective was to determine the effect of high-fat and non-fat food relative to fasting conditions on the 5 oral bioavailability of the compound of formula I when given as an oral suspension.
Twenty healthy subjects completed this randomized, open-label, 4-way crossover, single-dose bioavailability and food effect study of posaconazole.
Subjects received each of the following four treatments separated by at least a 7 day washout period:
Treatment A: 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) following a 10-hr.
fast Treatment B: 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) with a standardized high-fat breakfast Treatment C: 200 mg of the compound of formula I in the oral suspension of this invention (5 ml) with a standardized non-fat breakfast Treatment D: 2 x 100 mg of the compound of formula I in the tablets (co-precipitate formulation of U.S. Patent No. 5,834,472 with a standardized high-fat breakfast Subjects were randomized to either remain fasted (Treatment A), to receive a standardized high fat breakfast (Treatment B or D) or a standardized non-fat breakfast (Treatment C). Meals were consumed in a 20-minute period prior to the morning drug administration and subjects received the appropriate treatment within 5 minute of completing the breakfast.
Blood samples (6 ml) were collected into heparinized tubes for each treatment immediately prior to dosing (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after dosing. Blood was centrifuged at 4 C and plasma stored at or below -20 C until assayed. Plasma concentrations of posaconazole were assayed using a validated high performance liquid chromatographic assay with a LOQ of ng/ml.
Individual plasma concentration-time data were used for pharmacokinetic analysis using model-independent methods. The maximum concentration (Cmax) and time of maximum concentration (Tmax) were the observed values. The area to under the plasma concentration-time curve from time zero to the final quantifiable sampling time [AUC(tf)] was calculated using the linear trapezoidal method and extrapolated to infinity (I) as follows:
C(tf) AUC(I) = AUC(tf) K
where C(tf) is the estimated concentration determined from linear regression at time, tf.
Total body clearance was calculated by the following:
CL =Dose/ AUC(I) The apparent volume of distribution (Vdarea/F) was calculated from the ratio of the total body clearance to the terminal phase rate constant (K).
Summary statistics were calculated for the plasma suspension formulation of the present invention compared to a prior art tablet formulation concentration-time data at each time point and the derived pharmacokinetic parameters. The original scale and log-transformed Cmax and AUC values were analyzed using an analysis of variance (ANOVA). The effects due to subject, phase and treatment were extracted.
The plasma concentration-time data and pharmacokinetic parameters for the compound of formula I are tabulated in Tables 3 & 4 and depicted graphically in Figures 1 & 2.
All subjects had 0-hour concentrations on Day 1 reported as below the LOQ
(5 ng/ml) except for Subject 20 in Phases 3 and 4 who had quantifiable levels of posaconazole at 0-hour for Treatments B and A of 8.5 and 22.5 ng/ml, respectively.
io These levels are most likely due to a carry-over effect from accumulation from previous doses.
A summary of the meana pharmacokinetic parameters are provided in the table below:
Table 3 Tablet Suspension High Fat D 10 hr Fast A High Fat B Non-Fat C
Parameter Unit Mean %CV Mean %CV Mean %CV Mean %CV
Cmax ng/ml 413 33 132 50 512 34 378 43 Tmax Hr 5.5 32 5.01 49 4.8 9 4.1 21 AUC(tf) ng-hr/ml 10304 41 3553 36 13885 41 9511 38 AUC(I) ng-hr/ml 11832 39 4179 31 15059 26 10753 35 t%2 hr 21.0 15 23.5 25 23.0 19 22.2 18 a: Balanced means, n=20 except for AUC(I) and t'/2, n=1 5.
Posaconazole was slowly absorbed; the mean Tmax values ranged from 4.1 to 5.5 hr. Posaconazole was slowly eliminated with a mean terminal t1/2 of about 22 hour which was independent of treatment. This study was conducted to evaluate the bioavailability of posaconazole oral suspension (Treatment B) compared to a tablet formulation (Treatment D), both given with a high-fat food. The results, based on log-transformed data, are shown below:
Table 4 Treatments Relative 90%
Given After Bioavailability Confidence High Fat Geometric b Interval Parameter Breakfast Mean (%) Cmax Suspension 485 ng/ml 123.3 104-146 Tablet 394 ng/ml a Suspension 13141 ng.hr/ml 136.5 119-156 AUC(tf) Tablet 9624 ng.hr/ml a: AUC(tf) was used for statistical comparisons because it could be calculated for all treatments for all subjects.
b: Suspension relative to tablet.
On average, the suspension formulation of the present invention resulted in 1o a 23% increase in Cmax and a 36% increase in AUC(tf) compared to the tablet of the prior art.
The secondary objective of the study was to evaluate the effect of high fat food (Treatment B) and non-fat food (Treatment C) compared to fasting (Treatment A) on the oral bioavailability of posaconazole administered as an oral suspension.
The results, based on log-transformed data, are shown below:
Table 5 Relative Bioavailability 90%
Suspension Geometric a Confidence Parameter Treatments Mean (%) Interval Cmax High-Fat 485 417 352-493 (ng/ml) Non-Fat 345 296 250-350 Fast 116 -- --AUC(tf) High-Fat 13141 392 343-448 (ng.hr/ml Non-Fat 8857 264 231-302 Fast 3352 -- --a: Expressed as a percent of Treatment A - Suspension/Fast.
A high fat breakfast produced a 4-fold increase in the bioavailability of posaconazole given in a suspension. This was consistent with results from a previous study where food significantly increased the bioavailability of posaconazole by 3-5-fold for both tablet and capsule formulations. The effect of a non-fat breakfast (Treatment C) compared to fasting (Treatment A) was less, with a 2.5-3-fold increase in bioavailability.
Many modifications and variations of this invention can be made without io departing from its spirit and scope, as will be apparent to one skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims along with the full scope of equivalents to which such claims are entitled.
Claims (34)
1. A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I:
wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm, at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm, at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
2. The liquid suspension of claim 1, wherein the at least one non-ionic surfactant is a block copolymer of ethylene oxide and propylene oxide, glycol or glyceryl esters of saturated or unsaturated C8 to C20 acids, polyoxyethylene esters of saturated or unsaturated C8 to C20 acids, polyoxyethylene ethers of saturated or unsaturated C8 to C20 acids or polyvinylalcohols or sorbitan esters of saturated or unsaturated C10 to C20 acids.
3. The liquid suspension of claim 1, wherein the at least one non-ionic surfactant is a polyoxyethylene derivative of a sorbitan ester of a saturated or unsaturated C10 to C20 acid.
4. The liquid suspension of claim 1, wherein the at least one thickening agent is selected from the group consisting of xanthan gum, liquid sugars, starches, celluloses, and mixtures of two or more thereof.
5. The liquid suspension of claim 1, wherein a combination of xanthan gum and a liquid sugar is used as the at least one thickening agent.
6. The liquid suspension of claim 1, wherein the micronized compound of formula I has a mean particle size of about 1200 nm to about 1600 nm.
7. The liquid suspension of claim 1, comprising an amount of a buffer system effective to maintain the pH of the system in the range of about 4.0 to about 6Ø
8. The liquid suspension of claim 7, wherein the at least one non-ionic surfactant is a polyoxyethylene derivative of a sorbitan ester of a saturated or unsaturated C10 to C20 acid.
9. The liquid suspension of claim 8, wherein the sorbitan ester is one or more fatty acid ester of sorbitan selected from the group consisting of sorbitan monolaurate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, sorbitan monopalmitate, sorbitan monostearate and sorbitan tristearate.
10. The liquid suspension of claim 7, wherein the at least one thickening agent is selected from the group consisting of gums, liquid sugars, starches, celluloses, and mixtures of two or more thereof.
11. The liquid suspension of claim 7, wherein a combination of a xanthan gum and a liquid sugar is used as the at least one thickening agent.
12. The liquid suspension of claim 7, wherein a combination of a xanthan gum and a liquid glucose is used as the thickening agent.
13. The liquid suspension of claim 7, wherein the buffer system comprises sodium citrate and citric acid.
14. The liquid suspension of claim 7, wherein the pharmaceutically acceptable liquid carrier is a combination of purified water, glucose, and glycerin.
15. The liquid suspension of claim 7, wherein the micronized compound of formula I has a mean particle size of about 1200 nm to about 1600 nm.
16. The liquid suspension of claim 1, comprising:
a non-ionic surfactant which is a polyoxyethylene derivative of sorbitan esters of saturated or unsaturated C12 to C18 acids, a combination of two thickening agents, wherein one is a liquid sugar, and an effective amount of a buffer system sufficient to maintain a pH in the range of about 4.0 to about 6Ø
a non-ionic surfactant which is a polyoxyethylene derivative of sorbitan esters of saturated or unsaturated C12 to C18 acids, a combination of two thickening agents, wherein one is a liquid sugar, and an effective amount of a buffer system sufficient to maintain a pH in the range of about 4.0 to about 6Ø
17. The liquid suspension of claim 16, wherein the micronized compound of formula I has a mean particle size in the range of about 1200 nm to about 1600 nm.
18. A liquid suspension of claim 1 wherein the at least one thickening agent is xanthan gum.
19. The liquid suspension of claim 1, wherein the at least one non-ionic surfactant, is polyoxyethylene sorbitan monooleate.
20. The liquid suspension of claim 1, wherein the thickening agent is xanthan gum and a liquid sugar, and the non-ionic surfactant is a polyoxyethylene sorbitan monooleate.
21. The liquid suspension of claim 16, comprising a buffer system effective to maintain the pH of the system in the range of 4.0 to 6Ø
22. The liquid suspension of claim 21, wherein the buffer system comprises sodium citrate and citric acid.
23. A composition for at least one of treating and preventing a fungal infection in a patient, the composition in the form of a liquid, oral suspension comprising an antifungally effective amount of micronized particles of the compound of formula I:
wherein the micronized compound of formula I has a mean particle size of 1000 nm to 1800 nm, and the composition comprises at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
wherein the micronized compound of formula I has a mean particle size of 1000 nm to 1800 nm, and the composition comprises at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier.
24. The composition of claim 23, wherein the suspension is adapted to provide a maximum concentration (Cmax) of posaconazole in the plasma serum of 485 ng/ml to 512 ng/ml post-single dose administration.
25. The composition of claim 24, wherein the Cmax is measured at a time of maximum concentration (Tmax) in the range of 4 to 5 hours post-single dose administration.
26. The composition of claim 24, wherein a plot of the plasma concentration of posaconazole over time yields an Area Under the Curve over 72 hours [AUC(O-72 hrs)] value of posaconazole of 13141 ng-hr/ml to 13885 ng-hr/ml.
27. The composition of claim 24, wherein the Cmax of posaconazole is 485 ng/ml, and an Area Under the Curve over 72 hours [AUC(O-72 hrs)] value of posaconazole is 13141 ng-hr/ml.
28. The composition of claim 24, wherein the Cmax of posaconazole is 512 ng/ml, and an Area Under the Curve over 72 hours [AUC(O-72 hrs)] value of posaconazole is 13885 ng-hr/ml.
29. The composition of claim 24, wherein said liquid, oral suspension is adapted for administration with a high-fat meal to deliver 200 mg of posaconazole.
30. A composition for at least one of treating and preventing a fungal infection in a patient, the composition in the form of a liquid, oral suspension comprising an antifungally effective amount of a micronized compound of the chemical structural formula I:
wherein the micronized compound of formula I has a mean particle size of 1000 nm to 1800 nm, and the composition comprises at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier, and is adapted to provide a maximum concentration (Cmax) of posaconazole in the plasma serum that is 2.5 to 4 times greater when administered with a high-fat meal or a non-fat meal as compared to when administered following a 10 hr fast.
wherein the micronized compound of formula I has a mean particle size of 1000 nm to 1800 nm, and the composition comprises at least one thickening agent, at least one non-ionic surfactant, and a pharmaceutically acceptable liquid carrier, and is adapted to provide a maximum concentration (Cmax) of posaconazole in the plasma serum that is 2.5 to 4 times greater when administered with a high-fat meal or a non-fat meal as compared to when administered following a 10 hr fast.
31. The composition of claim 30, wherein the Cmax of posaconazole in the plasma serum is 4 times greater when administered with a high-fat meal as compared to when administered following a 10 hr fast.
32. The composition of claim 31, wherein said liquid, oral suspension is adapted for administration to deliver 200 mg of posaconazole.
33. Use of micronized particles of the compound of formula I
in the manufacture of a medicament in the form of a liquid, oral suspension for at least one of treating and preventing a fungal infection in a patient comprising an antifungally effective amount of the compound of formula I, wherein the medicament comprises at least one thickening agent, and least one surfactant and a pharmaceutically acceptable liquid carrier, wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm.
in the manufacture of a medicament in the form of a liquid, oral suspension for at least one of treating and preventing a fungal infection in a patient comprising an antifungally effective amount of the compound of formula I, wherein the medicament comprises at least one thickening agent, and least one surfactant and a pharmaceutically acceptable liquid carrier, wherein the micronized compound of formula I has a mean particle size of about 1000 nm to about 1800 nm.
34. The use of the liquid suspension as defined in claim 1, wherein the suspension is adapted to provide a maximum concentration (Cmax) of posaconazole in the plasma serum of about 485 ng/ml to about 512 ng/ml post-single dose administration.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28113901P | 2001-04-03 | 2001-04-03 | |
US60/281,139 | 2001-04-03 | ||
PCT/US2002/010093 WO2002080678A1 (en) | 2001-04-03 | 2002-04-01 | Antifungal composition with enhanced bioavailability |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2443089A1 CA2443089A1 (en) | 2002-10-17 |
CA2443089C true CA2443089C (en) | 2011-11-01 |
Family
ID=23076102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2443089A Expired - Lifetime CA2443089C (en) | 2001-04-03 | 2002-04-01 | Antifungal suspension of micronized posaconazole |
Country Status (18)
Country | Link |
---|---|
US (2) | US20030055067A1 (en) |
EP (2) | EP1372394A1 (en) |
JP (2) | JP4308902B2 (en) |
KR (1) | KR100607742B1 (en) |
CN (1) | CN100415234C (en) |
AR (1) | AR033096A1 (en) |
AU (1) | AU2002257104B2 (en) |
BR (1) | BR0208626A (en) |
CA (1) | CA2443089C (en) |
HU (1) | HUP0400856A3 (en) |
MX (1) | MXPA03009021A (en) |
NO (1) | NO20034419L (en) |
NZ (1) | NZ528363A (en) |
PE (1) | PE20020994A1 (en) |
PL (1) | PL212985B1 (en) |
TW (1) | TWI311464B (en) |
WO (1) | WO2002080678A1 (en) |
ZA (1) | ZA200307684B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20060160823A1 (en) * | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
KR20070027564A (en) * | 2004-05-28 | 2007-03-09 | 쉐링 코포레이션 | Injectable pharmaceutical suspension comprising posaconazole |
US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
MX2008015275A (en) * | 2006-05-30 | 2009-02-06 | Elan Pharma Int Ltd | Nanoparticulate posaconazole formulations. |
CA2660647C (en) | 2006-06-14 | 2015-07-28 | Intervet International B.V. | A suspension comprising benzimidazole carbamate and a polysorbate |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
FR2910323A1 (en) * | 2006-12-26 | 2008-06-27 | Virbac Sa Sa | Liquid anhydrous composition, useful e.g. to prepare oral medications that are diluted with drinking water to prevent/treat diseases of livestock, comprises active ingredient dissolved in organic solvents, surfactant and xanthan gum |
DE102008004893A1 (en) | 2008-01-17 | 2009-07-23 | Add Technologies Ltd. | Carrier pellets, process for their preparation and their use |
JP2011516613A (en) * | 2008-04-15 | 2011-05-26 | シェーリング コーポレイション | An oral pharmaceutical composition in a solid dispersion, preferably comprising posaconazole and HPMCAS |
EP2285351A2 (en) * | 2008-04-15 | 2011-02-23 | Schering Corporation | Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas |
EP2130540A1 (en) * | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
EP2141159A1 (en) | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
EP2451805A1 (en) | 2009-07-09 | 2012-05-16 | Sandoz AG | A crystalline form of posaconazole |
CN102906087B (en) | 2010-05-19 | 2016-03-23 | 桑多斯股份公司 | Prepare the method for chiral triazole ketone |
RU2580318C2 (en) | 2010-05-19 | 2016-04-10 | Сандоз Аг | Obtaining intermediate products for synthesis of posaconazole |
RU2585683C2 (en) | 2010-05-19 | 2016-06-10 | Сандоз Аг | Cleaning of posaconazole and intermediate products for synthesis of posaconazole |
EP2571847B1 (en) | 2010-05-19 | 2016-09-21 | Sandoz AG | Process for the preparation of chiral hydrazides |
CA2838051C (en) | 2011-06-16 | 2019-09-24 | Sandoz Ag | Process for the preparation of a chiral compound |
WO2013186320A1 (en) | 2012-06-14 | 2013-12-19 | Sandoz Ag | Pharmaceutical composition comprising crystalline posaconazole |
ES2786374T3 (en) | 2014-12-05 | 2020-10-09 | Pulmocide Ltd | Antifungal compound |
HUE048843T2 (en) * | 2015-05-21 | 2020-08-28 | Pulmocide Ltd | Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl )-n -(2-hydroxycyclohexyl)benzamide, or a pharmaceutically acceptable salt thereof. |
CN105030668B (en) * | 2015-06-26 | 2018-03-27 | 济川药业集团有限公司 | Oral posaconazole supensoid agent and preparation method thereof |
CN106333925B (en) * | 2015-07-10 | 2019-06-18 | 上海美悦生物科技发展有限公司 | A kind of posaconazole liquid suspension and preparation method thereof |
EA038421B1 (en) * | 2015-12-30 | 2021-08-26 | ВиПиЭс-3, ИНК. | Metalloenzyme inhibitor compounds |
CN106389390A (en) * | 2016-06-30 | 2017-02-15 | 重庆华邦制药有限公司 | Posaconazole coating agent and preparation method thereof |
CN107625729A (en) * | 2017-09-29 | 2018-01-26 | 重庆华邦制药有限公司 | Oral posaconazole suspension and preparation method thereof |
CN110507609B (en) * | 2018-05-21 | 2021-09-17 | 上海医药工业研究院 | Preparation method of posaconazole oral suspension |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
US4788220A (en) * | 1987-07-08 | 1988-11-29 | American Home Products Corporation (Del.) | Pediatric ibuprofen compositions |
NZ234143A (en) * | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
PL181193B1 (en) | 1993-12-21 | 2001-06-29 | Schering Corp | Tetrahydrofuranic antimycotic agents |
US5661151A (en) * | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
CA2238048A1 (en) * | 1995-11-20 | 1997-05-29 | Hiromasa Okada | Antifungal composition |
US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
US5846971A (en) | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
US6274634B1 (en) * | 1997-05-14 | 2001-08-14 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
ATE259220T1 (en) | 1998-05-29 | 2004-02-15 | Skyepharma Canada Inc | MICROPARTICLES PROTECTED AGAINST HEAT AND METHOD FOR THE TERMINAL STEAM STERILIZATION OF SAME |
US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
-
2002
- 2002-04-01 AU AU2002257104A patent/AU2002257104B2/en not_active Expired
- 2002-04-01 EP EP02726689A patent/EP1372394A1/en not_active Ceased
- 2002-04-01 US US10/114,612 patent/US20030055067A1/en not_active Abandoned
- 2002-04-01 HU HU0400856A patent/HUP0400856A3/en not_active Application Discontinuation
- 2002-04-01 CN CNB028077407A patent/CN100415234C/en not_active Expired - Lifetime
- 2002-04-01 CA CA2443089A patent/CA2443089C/en not_active Expired - Lifetime
- 2002-04-01 PL PL363965A patent/PL212985B1/en unknown
- 2002-04-01 JP JP2002578726A patent/JP4308902B2/en not_active Expired - Lifetime
- 2002-04-01 KR KR1020037012936A patent/KR100607742B1/en active IP Right Grant
- 2002-04-01 NZ NZ528363A patent/NZ528363A/en not_active IP Right Cessation
- 2002-04-01 WO PCT/US2002/010093 patent/WO2002080678A1/en active IP Right Grant
- 2002-04-01 EP EP09158184A patent/EP2090165A3/en not_active Withdrawn
- 2002-04-01 BR BR0208626-3A patent/BR0208626A/en not_active Application Discontinuation
- 2002-04-01 MX MXPA03009021A patent/MXPA03009021A/en active IP Right Grant
- 2002-04-02 PE PE2002000263A patent/PE20020994A1/en active IP Right Grant
- 2002-04-02 AR ARP020101198A patent/AR033096A1/en not_active Application Discontinuation
- 2002-04-02 TW TW091106644A patent/TWI311464B/en not_active IP Right Cessation
-
2003
- 2003-10-01 ZA ZA2003/07684A patent/ZA200307684B/en unknown
- 2003-10-02 NO NO20034419A patent/NO20034419L/en not_active Application Discontinuation
-
2008
- 2008-02-18 JP JP2008036719A patent/JP2008120836A/en active Pending
-
2011
- 2011-06-15 US US13/161,097 patent/US8263600B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PL212985B1 (en) | 2012-12-31 |
CN1499930A (en) | 2004-05-26 |
EP1372394A1 (en) | 2004-01-02 |
ZA200307684B (en) | 2005-03-30 |
AU2002257104B2 (en) | 2006-02-09 |
CA2443089A1 (en) | 2002-10-17 |
AR033096A1 (en) | 2003-12-03 |
KR20030087052A (en) | 2003-11-12 |
US8263600B2 (en) | 2012-09-11 |
EP2090165A3 (en) | 2012-03-28 |
JP2008120836A (en) | 2008-05-29 |
KR100607742B1 (en) | 2006-08-01 |
WO2002080678A1 (en) | 2002-10-17 |
TWI311464B (en) | 2009-07-01 |
US20110244004A1 (en) | 2011-10-06 |
MXPA03009021A (en) | 2004-02-12 |
CN100415234C (en) | 2008-09-03 |
BR0208626A (en) | 2004-03-09 |
HUP0400856A3 (en) | 2012-09-28 |
US20030055067A1 (en) | 2003-03-20 |
JP2004527525A (en) | 2004-09-09 |
EP2090165A2 (en) | 2009-08-19 |
JP4308902B2 (en) | 2009-08-05 |
NO20034419D0 (en) | 2003-10-02 |
NZ528363A (en) | 2005-04-29 |
PE20020994A1 (en) | 2002-11-01 |
HUP0400856A2 (en) | 2004-08-30 |
NO20034419L (en) | 2003-12-02 |
PL363965A1 (en) | 2004-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2443089C (en) | Antifungal suspension of micronized posaconazole | |
AU2002257104A1 (en) | Antifungal composition with enhanced bioavailability | |
RU2260428C2 (en) | Benzamide derivative-containing pharmaceutical composition eliciting enhanced solubility and absorption capacity in oral applying | |
JP5159012B2 (en) | Improved pharmaceutical composition for poorly soluble drugs | |
US5834472A (en) | Antifungal composition with enhanced bioavailability | |
US5846971A (en) | Oral antifungal composition | |
US20090176884A1 (en) | Pharmaceutical suspension composition | |
CA2258683C (en) | Oral composition comprising a triazole antifungal compound | |
US20040248901A1 (en) | Compositions containing itraconazole and their preparation methods | |
US4927638A (en) | Etoposide solutions | |
US20020028794A1 (en) | Megestrol acetate suspension | |
EP0914127B1 (en) | Antifungal composition with enhanced bioavailability | |
WO2006018814A2 (en) | Oral liquid suspensions of metaxalone | |
AU2006200354A1 (en) | Antifungal composition with enhanced bioavailability | |
US11890273B2 (en) | Losartan liquid formulations and methods of use | |
US20060141028A1 (en) | Cyclosporin formulations | |
KR20110042874A (en) | Suspension comprising megestrol acetate | |
US6207172B1 (en) | Composition for the delivery of a pharmaceutical agent to a patient | |
WO2023218482A1 (en) | Liquid oral formulation of apixaban or pharmaceutically acceptable salt thereof | |
SK126998A3 (en) | Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20220401 |